Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 5/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL4940620 | 0.93 | OPRL1 (0.49) | OPRL1ADRA1AMCHR1 | |
| SCHEMBL4935988 | 0.92 | OPRL1 (0.47) | OPRL1ADRA1AMCHR1NPY5RAVPR1A | |
| Citric Acid SCHEMBL4932708 | 0.91 | OPRL1 (0.41) | OPRL1ADRA1AMCHR1NPY5R | |
| Citric Acid SCHEMBL4932379 | 0.85 | OPRL1 (0.47) | OPRL1ADRA1AMCHR1 | |
| SCHEMBL4939794 | 0.84 | OPRL1 (0.56) | OPRL1ADRA1AMCHR1 | |
| SCHEMBL4897645 | 0.84 | ADRA1A (0.37) | OPRL1ADRA1AMCHR1AVPR1A | |
| SCHEMBL4932624 | 0.83 | OPRL1 (0.46) | OPRL1ADRA1AMCHR1NPY5RHRH3 | |
| Citric Acid SCHEMBL4932703 | 0.82 | OPRL1 (0.51) | OPRL1ADRA1AMCHR1NPY5RAVPR1A | |
| SCHEMBL4898388 | 0.81 | ADRA1A (0.37) | OPRL1ADRA1AMCHR1AVPR1A | |
| Citric Acid SCHEMBL4977727 | 0.78 | OPRL1 (0.65) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200490-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200490-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists | OPRL1, OPRD1, OGFRL1 | OPRL1 1/4885ADRA1A 36/4885MCHR1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.